Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PepGen Inc.

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Appointment of Two New Directors to its Board
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces CONNECT Program Updates
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Announces Executive Team Promotions
From PepGen Inc.
Via Business Wire
Tickers PEPG
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.